VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VTGN VistaGen Therapeutics, Inc.

已收盘 11-22 16:00:00 EST

2.58

+0.05

+1.98%

盘后2.60

+0.02+0.78%

19:37 EST

最高2.60	最低2.48	成交量26.62万
今开2.54	昨收2.53	日振幅4.74%
总市值6,980万	流通市值4,481万	总股本2,706万
成交额67.38万	换手率1.53%	流通股本1,737万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VTGN","market":"US","secType":"STK","nameCN":"VistaGen Therapeutics, Inc.","latestPrice":2.58,"timestamp":1732309200000,"preClose":2.53,"halted":0,"volume":266156,"hourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.58,"latestTime":"19:37 EST","volume":1923,"amount":4939.79,"timestamp":1732322233570},"delay":0,"floatShares":17369714,"shares":27055107,"eps":-1.307437,"marketStatus":"已收盘","marketStatusCode":5,"change":0.05,"latestTime":"11-22 16:00:00 EST","open":2.54,"high":2.6,"low":2.48,"amount":673824.217484,"amplitude":0.047431,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.307437,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":0,"listingDate":1462939200000,"adjPreClose":2.53,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":2.75,"preClose":2.53,"latestTime":"09:06 EST","volume":404,"amount":1022.7799744,"timestamp":1732284400769},"postHourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.58,"latestTime":"19:37 EST","volume":1923,"amount":4939.79,"timestamp":1732322233570},"volumeRatio":1.098831,"impliedVol":0.1876,"impliedVolPercentile":0.0437},"requestUrl":"/m/hq/s/VTGN/wiki","defaultTab":"wiki","newsList":[{"id":"2484783510","title":"Vistagen Therapeutics, Inc.2024财年第三财季实现净利润-12.96百万美元，同比减少96.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484783510","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484783510?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:03","pubTimestamp":1731773008,"startTime":"0","endTime":"0","summary":"11月17日，Vistagen Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-12.96百万美元，同比减少96.66%；其中营业收入为183000.00美元，同比减少34.10%，每股基本收益为-0.42美元。从资产负债表来看，Vistagen Therapeutics, Inc.总负债9.52百万美元，其中短期债务525000.00美元，资产负债比为0.11，流动比率为13.30。机构评级：截至2024年11月17日，当前有3家机构对Vistagen Therapeutics, Inc.目标价做出预测，其中目标均价为13.00美元，其中最低目标价为12.00美元，最高目标价为15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000441abc79103&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000441abc79103&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTGN","LENZ"],"gpt_icon":0},{"id":"2483630037","title":"Vistagen Therapeutics, Inc.盘中异动 快速下挫5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483630037","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483630037?lang=zh_cn&edition=full","pubTime":"2024-11-13 02:20","pubTimestamp":1731435647,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日02时20分，Vistagen Therapeutics, Inc.股票出现异动，股价大幅跳水5.29%。截至发稿，该股报2.86美元/股，成交量10.7255万股，换手率0.40%，振幅5.30%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.86%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Genprex, Inc.、Kairos Pharma, Ltd.涨幅较大，Genprex, Inc.、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为531.01%、426.42%、228.80%，振幅较大的相关个股有60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Geovax Labs Inc C/Wts 29/09/2025、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ，振幅分别为209.30%、105.45%、86.87%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111302204798e4227a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111302204798e4227a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VTGN","LENZ"],"gpt_icon":0},{"id":"2481129026","title":"Vistagen Therapeutics Inc    预计每股亏损 39 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2481129026","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481129026?lang=zh_cn&edition=full","pubTime":"2024-11-06 13:06","pubTimestamp":1730869619,"startTime":"0","endTime":"0","summary":"   * Vistagen Therapeutics Inc    将于11月7日公布截至2024年9月30日的财报，预计该公司的季度收入将出现下降。* 根据LSEG的数据，3位分析师的平均预期显示，这家总部位于加利福尼亚州旧金山南部的公司的营收预计将从去年同期的27.77万美元下降19.6%，至22.33万美元。* LSEG 分析师对 Vistagen Therapeutics Inc 的平均预期是每股亏损 39 美分。* 华尔街对 Vistagen Therapeutics Inc 的 12 个月目标价中位数为 12.00 美元，高于其上次收盘价 3.15 美元。11月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","VTGN"],"gpt_icon":0},{"id":"2473484671","title":"Vistagen Therapeutics, Inc.盘中异动 下午盘急速下跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2473484671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473484671?lang=zh_cn&edition=full","pubTime":"2024-10-08 02:15","pubTimestamp":1728324911,"startTime":"0","endTime":"0","summary":"北京时间2024年10月08日02时15分，Vistagen Therapeutics, Inc.股票出现波动，股价大幅下挫5.32%。截至发稿，该股报2.85美元/股，成交量10.9968万股，换手率0.41%，振幅4.98%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，Scholar Rock Holding Corporation、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Oncolytics Biotech Inc.涨幅较大，Aditxt, Inc.、Tc Biopharm  Plc、Phio Pharmaceuticals Corp.较为活跃，换手率分别为1628.95%、82.93%、60.41%，振幅较大的相关个股有Scholar Rock Holding Corporation、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Akari Therapeutics Plc，振幅分别为107.82%、39.46%、37.93%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008021511ab68223a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008021511ab68223a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","VTGN"],"gpt_icon":0},{"id":"2460671082","title":"Vistagen Therapeutics, Inc.2024财年第二财季实现净利润-10.73百万美元，同比减少55.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460671082","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460671082?lang=zh_cn&edition=full","pubTime":"2024-08-19 00:04","pubTimestamp":1723997094,"startTime":"0","endTime":"0","summary":"8月19日，Vistagen Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-10.73百万美元，同比减少55.51%；其中营业收入为84000.00美元，同比减少52.70%，每股基本收益为-0.35美元。从资产负债表来看，Vistagen Therapeutics, Inc.总负债8.75百万美元，其中短期债务567000.00美元，资产负债比为0.14，流动比率为0.18。机构评级：截至2024年8月19日，当前有3家机构对Vistagen Therapeutics, Inc.目标价做出预测，其中目标均价为13.00美元，其中最低目标价为12.00美元，最高目标价为15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408190005089f363e26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408190005089f363e26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VTGN"],"gpt_icon":0},{"id":"2459174639","title":"Vistagen Therapeutics, Inc.盘中异动 早盘股价大跌5.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459174639","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459174639?lang=zh_cn&edition=full","pubTime":"2024-08-14 21:31","pubTimestamp":1723642268,"startTime":"0","endTime":"0","summary":"北京时间2024年08月14日21时31分，Vistagen Therapeutics, Inc.股票出现异动，股价大幅下挫5.60%。截至发稿，该股报3.20美元/股，成交量5542股，换手率0.02%，振幅0.00%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.28%。其相关个股中，Conduit Pharmaceuticals Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Genprex, Inc.涨幅较大，Conduit Pharmaceuticals Inc.、Viracta Therapeutics, Inc.、Genprex, Inc.较为活跃，换手率分别为48.97%、42.56%、21.17%，振幅较大的相关个股有Acelyrin, Inc.、Cadrenal Therapeutics, Inc.、Genprex, Inc.，振幅分别为9.03%、8.82%、8.21%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408142131089f2ac09c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408142131089f2ac09c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTGN","LENZ","BK4139"],"gpt_icon":0},{"id":"2458526577","title":"Vistagen Therapeutics Inc    预计每股亏损 40 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2458526577","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458526577?lang=zh_cn&edition=full","pubTime":"2024-08-10 07:59","pubTimestamp":1723247953,"startTime":"0","endTime":"0","summary":"   * Vistagen Therapeutics Inc    预计将于8月13日公布截至2024年6月30日的财报。* 根据 LSEG 的数据，2 位分析师的平均预期显示，这家总部位于加利福尼亚州旧金山南部的公司预计将实现 30 万美元的营收。* LSEG 分析师对 Vistagen Therapeutics Inc 的平均预期是每股亏损 40 美分。* 华尔街对 Vistagen Therapeutics Inc 的 12 个月目标价中位数为 12.00 美元，高于其上次收盘价 3.41 美元。8月9日 - 本摘要于北京时间 8 月 9 日 23:59 机器生成。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","LENZ"],"gpt_icon":0},{"id":"2453712721","title":"Vistagen Therapeutics, Inc.盘中异动 股价大涨5.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453712721","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453712721?lang=zh_cn&edition=full","pubTime":"2024-07-23 03:33","pubTimestamp":1721676783,"startTime":"0","endTime":"0","summary":"北京时间2024年07月23日03时33分，Vistagen Therapeutics, Inc.股票出现异动，股价大幅上涨5.74%。截至发稿，该股报3.87美元/股，成交量3.2305万股，换手率0.12%，振幅6.83%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Pasithea Therapeutics Corp C/Wts 12/08/2026 、木薯科学涨幅较大，Hepion Pharmaceuticals, Inc.、Scisparc Ltd.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为123.93%、117.41%、86.85%，振幅较大的相关个股有Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 、Anew Medical Inc C/Wts 21/06/2029 、Mei Pharma, Inc.，振幅分别为53.55%、44.07%、37.06%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723033303aefacee9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723033303aefacee9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTGN","LENZ","BK4139"],"gpt_icon":0},{"id":"2450809072","title":"Vistagen Therapeutics, Inc.盘中异动 下午盘大幅拉升5.16%报3.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450809072","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450809072?lang=zh_cn&edition=full","pubTime":"2024-07-10 03:30","pubTimestamp":1720553401,"startTime":"0","endTime":"0","summary":"北京时间2024年07月10日03时30分，Vistagen Therapeutics, Inc.股票出现波动，股价快速拉升5.16%。截至发稿，该股报3.57美元/股，成交量7.1675万股，换手率0.27%，振幅3.54%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。其相关个股中，Soligenix, Inc.、Uniqure N.V.、180 Life Sciences Corp.涨幅较大，Soligenix, Inc.、180 Life Sciences Corp.、Zyversa Therapeutics, Inc.较为活跃，换手率分别为13243.62%、3230.25%、368.30%，振幅较大的相关个股有Soligenix, Inc.、180 Life Sciences Corp.、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为468.99%、196.29%、134.00%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710033002aef8c223&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710033002aef8c223&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTGN","LENZ","BK4139"],"gpt_icon":0},{"id":"2442582151","title":"VistaGen Therapeutics(VTGN.US)：2024年Q4财报实现营收19.73万美元，前值为17.56万美元，预期值为41万美元；","url":"https://stock-news.laohu8.com/highlight/detail?id=2442582151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442582151?lang=zh_cn&edition=full","pubTime":"2024-06-12 16:33","pubTimestamp":1718181239,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","VTGN","BK4139"],"gpt_icon":0},{"id":"2442328785","title":"Vistagen Therapeutics Inc 报告截至 3 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2442328785","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442328785?lang=zh_cn&edition=full","pubTime":"2024-06-12 06:08","pubTimestamp":1718143705,"startTime":"0","endTime":"0","summary":"   * Vistagen Therapeutics Inc   报告，截至3月底的季度调整后每股亏损25美分，高于去年同期的每股收益1.75美元。四位分析师对该季度的平均预期是每股亏损 36 美分。华尔街预期为每股-46美分至-27美分。* Vistagen Therapeutics Inc 公布的本季度每股收益为亏损 25 美分。* 该公司当季亏损 952 万美元。* Vistagen Therapeutics Inc 的股价本季度下跌了 30.3%，今年迄今为止下跌了 28.4%。华尔街对 Vistagen Therapeutics Inc 的 12 个月目标价中位数为 12.00 美元。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","VTGN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vistagen.com","stockEarnings":[{"period":"1week","weight":-0.0733},{"period":"1month","weight":-0.1839},{"period":"3month","weight":-0.3106},{"period":"6month","weight":-0.3799},{"period":"1year","weight":-0.2448},{"period":"ytd","weight":-0.5078}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vistagen Therapeutics, Inc.成立于1998年5月26日，是一家临床阶段的生物制药公司，致力于开发新一代治疗焦虑、抑郁和某些其他中枢神经系统(CNS)疾病的疗法，这些疾病目前的治疗方案不足，导致全球大型和不断增长的市场存在大量未满足的需求，产品线包括三种临床阶段的CNS候选产品，PH94B、PH10和AV-101，每种产品都具有不同的作用机制，迄今为止在所有临床研究中都具有卓越的安全性，并且在多种CNS适应症中具有治疗潜力。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.1807},{"month":2,"riseRate":0.25,"avgChangeRate":-0.126424},{"month":3,"riseRate":0.25,"avgChangeRate":-0.122695},{"month":4,"riseRate":0.625,"avgChangeRate":0.021656},{"month":5,"riseRate":0.5,"avgChangeRate":-0.012139},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.071169},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.078003},{"month":8,"riseRate":0.777778,"avgChangeRate":0.280685},{"month":9,"riseRate":0.222222,"avgChangeRate":0.029646},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.080749},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.104927},{"month":12,"riseRate":0.75,"avgChangeRate":0.308966}],"exchange":"NASDAQ","name":"VistaGen Therapeutics, Inc.","nameEN":"VistaGen Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供VistaGen Therapeutics, Inc.(VTGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"VistaGen Therapeutics, Inc.,VTGN,VistaGen Therapeutics, Inc.股票,VistaGen Therapeutics, Inc.股票老虎,VistaGen Therapeutics, Inc.股票老虎国际,VistaGen Therapeutics, Inc.行情,VistaGen Therapeutics, Inc.股票行情,VistaGen Therapeutics, Inc.股价,VistaGen Therapeutics, Inc.股市,VistaGen Therapeutics, Inc.股票价格,VistaGen Therapeutics, Inc.股票交易,VistaGen Therapeutics, Inc.股票购买,VistaGen Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供VistaGen Therapeutics, Inc.(VTGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}